Pancreatic Cancer

Medicine

Your browser is too old

We can't provide a great video experience on old browser

Update now
Data 2fimages 2fmcxv6nubqjahzofzytr8 190131 s0 mushtaq saima pancreatic cancer intro
02:21
Pancreatic Cancer
Data 2fimages 2fehy0bexaraszisbqahp6 190131 s1 mushtaq saima genetic and molecular considerations
11:13
Genetic and Molecular Considerations
Data 2fimages 2fl7ldeg69qmdljpge4szg 190131 s2 mushtaq saima clinical presentation
10:05
Clinical Presentation
Data 2fimages 2fg421wrr7w1bl1thi6kbw 190131 s3 mushtaq saima diagnosis and staging
11:22
Diagnosis and Staging
Data 2fimages 2fomgefbgdshcsummzobrx 190131 s4 mushtaq saima treatment
10:10
Treatment

Lecture´s Description

Genetic and Molecular Considerations

Pancreatic cancer begins in the tissues of pancreas. Risk factors associated with pancreatic cancer include cigarette smoking, history of diabetes, obesity. The four genes most commonly mutated or inactivated in pancreatic cancer are KRAS, the tumor-suppressor genes p16, p53, and SMAD4.  Germline mutations in the following genes are associated with a significantly increased risk of pancreatic cancer and other cancers i.e. STK11 gene, BRCA2, p16/CDKN2A, PALB2, HMLH1 and MSH2, and ATM. Endoscopic ultrasound is a more promising screening tool.

Clinical Presentation

Main duct intraductal mucinous papillary neoplasms (IPMNS) are more likely to occur in older persons and have higher malignant potential than branched duct IPMNS. Mucinous cystic neoplasms (MCNS) are solitary lesions of the distal pancreas that do not communicate with the duct system. Clinically, obstructive jaundice occurs frequently when the cancer is located in the head of the pancreas. This may be accompanied by symptoms of abdominal discomfort, pruritus, lethargy, and weight loss.

Diagnosis and Staging

Patients of pancreatic cancer undergo imaging to confirm the presence of a tumor. Dual-phase, contrast-enhanced spiral CT and endoscopic retrograde cholangiopancreatography (ERCP) are useful for revealing pancreatic lesions. Percutaneous biopsy is only acceptable in patients with inoperable or metastatic disease. Preoperative CA19-9 levels of serum marker correlate with tumor stage, and postresection CA19-9 level has prognostic value. The information of the location and size of the tumor, the involvement of lymph nodes, and distant metastasis is combined to assign a stage.

Treatment

Patients with localized nonmetastatic disease are potentially suitable for surgical resection. Approx. 30% of patients have R1 resection following surgery. Those who undergo R0 resection and who receive adjuvant treatment have the best chance of cure. The standard surgical procedure is a pylorus-preserving pancreaticoduodenectomy. The use of gemcitabine after complete resection significantly delayed the development of recurrent disease compared with surgery alone.  Patients who respond to chemotherapy have frequently been offered consolidation radiotherapy.

Studies have shown that V-Learning™ increases student's learning and passing rate Significantly.

100% satisfaction guaranteed, join us & boost your medical Knowledge